India Flouting Own Patent Law By Giving IP Protection To Undeserving Drugs?
India is known for its strict patent legislation restricting which drugs can be given IP protection, but a new study suggests authorities in the country are actually being too lenient in awarding patents in a rush to grant new applications.
You may also be interested in...
USTR's 2018 Special 301 Report moves two countries to Priority Watch List in part because of their pricing policies; AAM says focus should be on government reimbursement rather than extending IP protection.
India has awarded Pfizer a patent for its blockbuster pneumonia vaccine Prevnar13, handing the pharmaceutical giant a big victory in a case which has been closely watched as a key test of the country’s patentability criteria.
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.